Joydeep Das

Dr. Joydeep Das


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NGNoyel Ghosh
Noyel Ghosh
MKMousumi Kundu
Mousumi Kundu
SGSumit Ghosh
Sumit Ghosh
ADAbhishek Kumar Das
Abhishek Kumar Das
SDSamhita De
Samhita De
PSParames Sil
Parames Sil

6 November 2023 in Heliyon
Verified
Journal Article
Open access
STSaloni Thakur
Saloni Thakur
RSReena V. Saini
Reena V. Saini
NTNeelam Thakur
Neelam Thakur
RSRohit Sharma
Rohit Sharma
JDJoydeep Das
Joydeep Das
ASAdesh Saini
Adesh Saini
These days carbon dots have been developed for multiple biomedical applications. In the current study, the transfection potential of synthesized carbon dots from single biopolymers such as chitosan, PEI-2kDa, and PEI-25kDa (CS-CDs, PEI2-CDs, and PEI25-CDs) and by combining two biopolymers (CP2-CDs and CP25-CDs) through a bottom-up approach have been investigated. The characterization studies revealed successful synthesis of fluorescent, positively charged carbon dots <20 nm in size. Synthesized carbon dots formed a stable complex with plasmid DNA (EGFP-N1) and miRNA-153 that protected DNA/miRNA from serum-induced degradation. In-vitro cytotoxicity analysis revealed minimal cytotoxicity in cancer cell lines (A549 and MDA-MB-231). In-vitro transfection of EGFP-N1 plasmid DNA with PEI2-CDs, PEI25-CDs and CP25-CDs demonstrated that these CDs could strongly transfect A549 and MDA-MB-231 cells. The highest EGFP-N1 plasmid transfection efficiency was observed with PEI2-CDs at a weight ratio of 32:1. PEI25-CDs polyplex showed maximum transfection at a weight ratio of 8:1 in A549 at a weight ratio of 16:1 in MDA-MB-231 cells. CP25-CDs exhibited the highest transfection at a weight ratio of 16:1 in both cell lines. The in-vitro transfection of target miRNA, i.e., miR-153 in A549 and MDA-MB-231 cells with PEI2-CDs, PEI25-CDs, and CP25-CDs suggested successful transfer of miR-153 into cells which induced significant cell death in both cell lines. Importantly, CS-CDs and CP2-CDs could be tolerated by cells up to 200 μg/mL concentration, while PEI2-CDs, PEI25-CDs, and CP25-CDs showed non-cytotoxic behavior at low concentrations (25 μg/mL). Together, these results suggest that a combination of carbon dots synthesized from chitosan and PEI (CP25-CDs) could be a novel vector for transfection nucleic acids that can be utilized in cancer therapy.

19 August 2022 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
NTNeelam Thakur
Neelam Thakur
MKMousumi Kundu
Mousumi Kundu
SCSharmistha Chatterjee
Sharmistha Chatterjee
TSTh. Abhishek Singh
Th. Abhishek Singh
JDJoydeep Das
Joydeep Das
PSParames Sil
Parames Sil

9 September 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NGNoyel Ghosh
Noyel Ghosh
MKMousumi Kundu
Mousumi Kundu
SGSumit Ghosh
Sumit Ghosh
ADAbhishek Kumar Das
Abhishek Kumar Das
SDSamhita De
Samhita De
PSParames Sil
Parames Sil

16 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
S. IslamS. Islam
S. Islam
Subbroto SahaSubbroto Saha
Subbroto Saha
SEShaker EL-Sappagh
Shaker EL-Sappagh
Faisal TariqFaisal Tariq
Faisal Tariq
JDJoydeep Das
Joydeep Das
Ssang-Goo ChoSsang-Goo Cho
Ssang-Goo Cho
GRINA is an emerging target for cancer therapy. However, the role of GRINA expression and its correlation with cancer patient survival has not been comprehensively studied. Here, we found that mRNA and protein expression of GRINA was upregulated in breast, colon, gastric, and prostate cancers and negatively correlated with patient survival. Also, the upregulation of GRINA expression is associated with hypomethylation of its promoter region. Our GRINA-miRNAs network analysis revealed potential regulatory miRNAs regulating the GRINA expression and its downstream pathways. Next, functional enrichment and pathway analysis of genes commonly co-express with GRINA in breast, colon, gastric, and prostate cancers revealed GRINA regulatory pathways. Concurrently, our upstream regulator analysis revealed possible kinases, transcription factors, and proteins that may potentially regulate GRINA . Overall, this study demonstrates the prognostic significance of GRINA expression and identifies potential regulatory mechanisms, which might have significant implications in targeted therapies for human cancers.